In this study, we also found that hepatic IGFBP2 levels decreased in NASH in all of the three human mRNA datasets as well as in the animal model, suggesting the potential of IGFBP2 to be a noninvasive biomarker for the diagnosis of NASH. The gene discussed is IGFBP2; the disease is metabolic dysfunction-associated steatohepatitis.